Law Offices of Howard G. Smith announces an investigation on behalf of Vanda Pharmaceuticals Inc. investors (Vanda or the Company) (NASDAQ: VNDA) concerning the Company and its officers possible violations of federal securities laws.
On February 11, 2019, Aurelius Value published an article reporting that a Qui Tam lawsuit filed by a whistleblower was recently unsealed, containing allegations of illegal off-label promotion of both of Vandas drugs, Vandas participation in a fraud involving doctors writing hundreds of ˜fake prescriptions and pocketing cash using Vanda-issued copay cards, falsified documents in internal systems, and resignations of senior executives who refused to participate in illegal activity. On this news, Vandas share price fell, thereby injuring investors.
If you purchased Vanda securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.